Treatment of Neuromyelitis Optica: Review and Recommendations.
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to tr...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826303198286053376 |
|---|---|
| author | Kimbrough, D Fujihara, K Jacob, A Lana-Peixoto, M Leite, M Levy, M Marignier, R Nakashima, I Palace, J de Seze, J Stuve, O Tenembaum, SN Traboulsee, A Waubant, E Weinshenker, BG Wingerchuk, D |
| author_facet | Kimbrough, D Fujihara, K Jacob, A Lana-Peixoto, M Leite, M Levy, M Marignier, R Nakashima, I Palace, J de Seze, J Stuve, O Tenembaum, SN Traboulsee, A Waubant, E Weinshenker, BG Wingerchuk, D |
| author_sort | Kimbrough, D |
| collection | OXFORD |
| description | Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices. |
| first_indexed | 2024-03-07T05:59:01Z |
| format | Journal article |
| id | oxford-uuid:eb86b665-b59c-4e1e-ab10-c5e2488b9f81 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:59:01Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:eb86b665-b59c-4e1e-ab10-c5e2488b9f812022-03-27T11:10:28ZTreatment of Neuromyelitis Optica: Review and Recommendations.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:eb86b665-b59c-4e1e-ab10-c5e2488b9f81EnglishSymplectic Elements at Oxford2012Kimbrough, DFujihara, KJacob, ALana-Peixoto, MLeite, MLevy, MMarignier, RNakashima, IPalace, Jde Seze, JStuve, OTenembaum, SNTraboulsee, AWaubant, EWeinshenker, BGWingerchuk, DNeuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices. |
| spellingShingle | Kimbrough, D Fujihara, K Jacob, A Lana-Peixoto, M Leite, M Levy, M Marignier, R Nakashima, I Palace, J de Seze, J Stuve, O Tenembaum, SN Traboulsee, A Waubant, E Weinshenker, BG Wingerchuk, D Treatment of Neuromyelitis Optica: Review and Recommendations. |
| title | Treatment of Neuromyelitis Optica: Review and Recommendations. |
| title_full | Treatment of Neuromyelitis Optica: Review and Recommendations. |
| title_fullStr | Treatment of Neuromyelitis Optica: Review and Recommendations. |
| title_full_unstemmed | Treatment of Neuromyelitis Optica: Review and Recommendations. |
| title_short | Treatment of Neuromyelitis Optica: Review and Recommendations. |
| title_sort | treatment of neuromyelitis optica review and recommendations |
| work_keys_str_mv | AT kimbroughd treatmentofneuromyelitisopticareviewandrecommendations AT fujiharak treatmentofneuromyelitisopticareviewandrecommendations AT jacoba treatmentofneuromyelitisopticareviewandrecommendations AT lanapeixotom treatmentofneuromyelitisopticareviewandrecommendations AT leitem treatmentofneuromyelitisopticareviewandrecommendations AT levym treatmentofneuromyelitisopticareviewandrecommendations AT marignierr treatmentofneuromyelitisopticareviewandrecommendations AT nakashimai treatmentofneuromyelitisopticareviewandrecommendations AT palacej treatmentofneuromyelitisopticareviewandrecommendations AT desezej treatmentofneuromyelitisopticareviewandrecommendations AT stuveo treatmentofneuromyelitisopticareviewandrecommendations AT tenembaumsn treatmentofneuromyelitisopticareviewandrecommendations AT traboulseea treatmentofneuromyelitisopticareviewandrecommendations AT waubante treatmentofneuromyelitisopticareviewandrecommendations AT weinshenkerbg treatmentofneuromyelitisopticareviewandrecommendations AT wingerchukd treatmentofneuromyelitisopticareviewandrecommendations |